Home LiteratureArticle Details
PMID: 14610198 Published · ppublish English Journal Article

Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.

Journal of virology ·Vol. 77 ·No. 23 ·2003-12-00 ·Pages 12764-72

Kong WP, Huang Y, Yang ZY, Chakrabarti BK, Moodie Z, Nabel GJ

Abstract

The ability to elicit an immune response to a spectrum of human immunodeficiency virus type 1 (HIV-1) gene products from divergent strains is a desirable feature of an AIDS vaccine. In this study, we examined combinations of plasmids expressing multiple HIV-1 genes from different clades for their ability to elicit humoral and cellular immune responses in mice. Immunization with a modified Env, gp145DeltaCFI, in combination with a Gag-Pol-Nef fusion protein plasmid elicited similar CD4(+) and CD8(+) cellular responses to immunization with either vector alone. Further, when mice were immunized with a mixture of Env from three clades, A, B, and C, together with Gag-Pol-Nef, the overall potency and balance of CD4(+)- and CD8(+)-T-cell responses to all viral antigens were similar, with only minor differences noted. In addition, plasmid mixtures elicited antibody responses comparable to those from individual inoculations. These findings suggest that a multigene and multiclade vaccine, including components from A, B, and C Env and Gag-Pol-Nef, can broaden antiviral immune responses without immune interference. Such combinations of immunogens may help to address concerns about viral genetic diversity for a prospective HIV-1 vaccine.

MeSH Terms
AIDS Vaccines/immunology Animals Enzyme-Linked Immunosorbent Assay Flow Cytometry Genes, Viral HIV Antibodies/biosynthesis HIV-1/genetics,immunology Mice Vaccines, DNA/immunology
Chemicals
AIDS Vaccines HIV Antibodies Vaccines, DNA
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Kong Wing-Pui
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-3005, USA.
Huang Yue
Yang Zhi-Yong
Chakrabarti Bimal K
Moodie Zoe
Nabel Gary J
References (40)
40 references, click to expand
  1. Recombinant viruses as a tool for therapeutic vaccination against human cancers.
    Immunol Lett. 2000 Sep 15;74(1):11-25 PMID: 10996623
  2. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.
    J Exp Med. 1999 Mar 15;189(6):991-8 PMID: 10075982
  3. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
    Science. 2000 Oct 20;290(5491):486-92 PMID: 11039923
  4. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
    Science. 2001 Apr 6;292(5514):69-74 PMID: 11393868
  5. Challenges and opportunities for development of an AIDS vaccine.
    Nature. 2001 Apr 19;410(6831):1002-7 PMID: 11309631
  6. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.
    J Virol. 2001 May;75(10):4947-51 PMID: 11312370
  7. Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines.
    Virology. 2001 May 25;284(1):46-61 PMID: 11352667
  8. Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53.
    Eur J Immunol. 2001 Jun;31(6):1747-56 PMID: 11385619
  9. Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization.
    Virology. 2001 Jul 5;285(2):204-17 PMID: 11437655
  10. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry.
    J Immunol Methods. 2001 Sep 1;255(1-2):27-40 PMID: 11470284
  11. Vaccines for the prevention of HIV-1 disease.
    Curr Opin Immunol. 2001 Aug;13(4):489-95 PMID: 11498307
  12. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design.
    J Virol. 2001 Oct;75(19):9210-28 PMID: 11533184
  13. Frequency and function of HIV-specific CD8(+) T cells.
    Immunol Lett. 2001 Nov 1;79(1-2):141-50 PMID: 11595301
  14. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.
    J Virol. 2001 Nov;75(22):10991-1001 PMID: 11602739
  15. Vaccine protection against functional CTL abnormalities in simian human immunodeficiency virus-infected rhesus monkeys.
    J Immunol. 2002 Jan 1;168(1):332-7 PMID: 11751978
  16. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Nature. 2002 Jan 17;415(6869):331-5 PMID: 11797011
  17. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.
    Nature. 2002 Jan 17;415(6869):335-9 PMID: 11797012
  18. Muscle specific versus ubiquitous expression of Gag based HIV-1 DNA vaccines: a comparative analysis.
    Vaccine. 2002 May 6;20(15):1975-9 PMID: 11983257
  19. Issues for improving multiplasmid DNA vaccines for HIV-1.
    Vaccine. 2002 May 6;20(15):1999-2003 PMID: 11983262
  20. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.
    J Virol. 2002 Jun;76(11):5357-68 PMID: 11991964
  21. Strategies for an HIV vaccine.
    J Clin Invest. 2002 Jul;110(1):15-20 PMID: 12093882
  22. Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays.
    AIDS Res Hum Retroviruses. 2002 Sep 20;18(14):1067-79 PMID: 12396458
  23. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
    J Virol. 2003 Feb;77(4):2310-20 PMID: 12551968
  24. Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.
    J Virol. 2003 Jun;77(11):6197-207 PMID: 12743276
  25. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant.
    Lancet. 1993 Apr 3;341(8849):860-1 PMID: 8096564
  26. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
    J Virol. 1994 Jul;68(7):4650-5 PMID: 8207839
  27. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.
    J Virol. 1994 Sep;68(9):6103-10 PMID: 8057491
  28. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.
    J Exp Med. 1995 Apr 1;181(4):1365-72 PMID: 7699324
  29. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors.
    Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5773-7 PMID: 7597028
  30. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women.
    Nat Med. 1995 Jan;1(1):59-64 PMID: 7584954
  31. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
    Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11341-8 PMID: 8876137
  32. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors.
    Immunol Cell Biol. 1997 Aug;75(4):382-8 PMID: 9315482
  33. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.
    N Engl J Med. 1997 Oct 30;337(18):1267-74 PMID: 9345075
  34. Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine.
    J Virol. 1998 Feb;72(2):1403-10 PMID: 9445041
  35. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins.
    Science. 1998 Feb 13;279(5353):1034-7 PMID: 9461435
  36. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.
    Science. 1998 Mar 27;279(5359):2103-6 PMID: 9516110
  37. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi.
    J Clin Invest. 1998 Nov 1;102(9):1758-65 PMID: 9802890
  38. Genetic variation of HIV type 1: relevance of interclade variation to vaccine development.
    AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S211-21 PMID: 9814946
  39. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
    Science. 1999 Feb 5;283(5403):857-60 PMID: 9933172
  40. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.
    J Virol. 2000 Nov;74(21):10249-55 PMID: 11024158
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2003-12-00
Pages
12764-72
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC262562
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com